Anoro Ellipta Prices, Coupons, Copay Cards & Patient Assistance
Anoro Ellipta (umeclidinium/vilanterol) is a member of the bronchodilator combinations drug class and is commonly used for COPD, and COPD - Maintenance.
The cost for Anoro Ellipta (62.5 mcg-25 mcg/inh) inhalation powder is around $135 for a supply of 14 powder, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Anoro Ellipta is available as a brand name drug only, a generic version is not yet available. View generic Anoro Ellipta availability for more details.
Anoro Ellipta prices
Inhalation Powder
62.5 mcg-25 mcg/inh
Anoro Ellipta inhalation powder
from $135.48
for 14 powder
Quantity | Per unit | Price |
---|---|---|
14 | $9.68 | $135.48 |
60 | $8.87 | $532.12 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Anoro Ellipta Coupons, Copay Cards and Rebates
Anoro Ellipta offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
No manufacturer promotions could be found for this medication.
Patient Assistance & Copay Programs for Anoro Ellipta
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: GSK Patient Assistance Program
Eligibility requirements:- Must be uninsured
- At or below 300% of FPL
- Not required
- The patient must live in one of the 50 states, the District of Columbia, or Puerto Rico* and utilize the US healthcare system
- Patients may apply on their own or with the help of an advocate. Fax or mail enrollment documents to the program with patient name and date of birth on each page (faxed prescriptions are only valid if faxed directly from a prescriber's office). Eligible patients may receive 90 day supply of medicine to their home within 7 days of faxed enrollment (mailed enrollments may take longer to receive medicine). If enrollment documents are submitted by mail, submit ONLY COPIES of Proof of Household Income documents. Do not mail original income or tax documents. Documents submitted cannot be returned. *Puerto Rico Residents do not qualify for vaccine products.
- Anoro Ellipta (umeclidinium-vilanterol)
More information please phone: 866-728-4368 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
More about Anoro Ellipta (umeclidinium / vilanterol)
- Check interactions
- Compare alternatives
- Reviews (69)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: bronchodilator combinations
- En español
Patient resources
Professional resources
- Anoro Ellipta prescribing information
- Umeclidinium and Vilanterol (Oral Inhalation) (AHFS Monograph)